Aprea Therapeutics, Inc. · NASDAQ:APRE

Aprea Therapeutics — Investor Presentation (May 2023)

25 slides from Aprea Therapeutics's investor presentation, May 15, 2023

  1. Slide 1: Precision Oncology through Synthetic Lethality May 2023

    Precision Oncology through Synthetic Lethality May 2023

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our clinical trials, regula

  3. Slide 3: Precision Oncology via Synthetic Lethality in Defined Patient Populations

    © 2023 Aprea Therapeutics, Inc. All Rights Reserved. 3 ▪ Clinical stage precision oncology company developing novel synthetic lethality-based therapeutics in areas of high unmet need ◊ ATRN-119: ATR Inhibitor ◊ ATRN-1051: WEE1 Inhibitor ◊ Undisclosed DDR Inhibitor ▪ Synthetic lethality assets potent

  4. Slide 4: Robust DDR Development Pipeline

    Robust DDR Development Pipeline 1 ATRN-354 timeline and anticipated milestones subject to data from ATRN-119 clinical trial © 2023 Aprea Therapeutics, Inc. All Rights Reserved. 4

  5. Slide 5: Repli-Biom Proprietary Platform and Combination Approaches

    Repli-Biom Proprietary Platform and Combination Approaches An Integrated Platform for Discovery of Novel SL Targets and Biomarkers 5 Drug response factor identification ▪ Repli-Biom platform is designed to identify factors that respond to drug treatment at the mechanistic site of drug action, the re

  6. Slide 6: ATRN-119 ATR Inhibitor

    ATRN-119 ATR Inhibitor © 2023 Aprea Therapeutics, Inc. All Rights Reserved. 6

  7. Slide 7: ATR is the Master Regulator of DDR

    ATR is the Master Regulator of DDR ▪ Defects in DDR lead to compromised genomic instability and stalling of the replication fork ▪ ATR is activated by replication stress ▪ ATR Inhibition leads to replication fork collapse and cancer cell death ◊ Cancer cells with dysfunctional and/or dysregulated DD

  8. Slide 8: ATRN-119 Preclinical Profile

    ATRN-119 Preclinical Profile ▪ Nanomolar potency in vitro across a broad spectrum of cancer cell lines ▪ Based on pre-clinical studies, strong tumor control observed in vivo, including in challenging genetic backgrounds © 2023 Aprea Therapeutics, Inc. All Rights Reserved. 8 Pre-clinical studies with

  9. Slide 9: ATRN-119 + Olaparib: Regression of BRCA2-Deficient Ovarian Tumors

    ATRN-119 + Olaparib: Regression of BRCA2-Deficient Ovarian (HGSOC) Tumors 9 ATRN-119 + Olaparib Inhibits Ovarian Tumor Growth Over Time ATRN-119 + Olaparib Shows Negligible Weight Loss Over Time © 2023 Aprea Therapeutics, Inc. All Rights Reserved. Pre-clinical studies with ATRN-119 N=6-8 mice per gr

  10. Slide 10: ATRN-119 is Potentially Differentiated from Other ATR Inhibitors

    ATRN-119 is Potentially Differentiated from Other ATR Inhibitors ▪ ATRN-119 has shown the potential to be highly potent with high selectivity to limit off-target toxicity 10 Note: Head-to-head studies with ATRN-119 have not been conducted (1) Atrin data reported for HCT116 - Bcl/XL cell line; (2) Fo

  11. Slide 11: Comparison of Clinical Parameters of Other ATR Inhibitors

    11 Parameter AstraZeneca AZD6738 (1)(2) Bayer BAY1895344 (3) Repare / Roche(4) RP-3500 (5) Route Of Administration Oral Oral Oral Clinical Studies Chosen (MTD/RP2D), Dose Schedule 160mg BID, 2-weeks-on, 2-weeks-off, or: Continuous dosing (1) 40mg BID, 3-days-on/4-days-off 160mg QD, 3-days-on/4-days-

  12. Slide 12: ATRN-119 Daily Dosing Is Desirable

    ATRN-119 Daily dosing Is Desirable Lack of daily dosing may contribute to formation of resistance © 2023 Aprea Therapeutics, Inc. All Rights Reserved. 12 Cancer cell proliferation Drug “On” Drug “Off” Drug “On” Cancer cell death/ decreased rate of proliferation Continuous dosing Intermittent dosing

  13. Slide 13: ATRN-119 Dosing and Toxicology Parameters

    13 Parameter ATRN-119 (1) Route Of Administration Oral Clinical Studies Chosen (MTD/RP2D), Dose Schedule continuous once-daily dosing (dose TBD in Phase 1) (1) Hematological toxicities in preclinical studies Pre-Clinical, Toxicology Studies: • In 28-day GLP tox study in dogs, hematological changes w

  14. Slide 14: ATRN-119 Phase 1/2a Clinical Trial

    ATRN-119 Phase 1/2a Clinical Trial 14 Trial Objectives: • Primary: MTD / RP2D; safety; tolerability; PK • Secondary: ORR • Exploratory: PD; PK/PD relationships; bioavailability; predictive value of DDR biomarkers Patients with advanced solid tumors with at least one DDR mutation Part 1 : Dose Escala

  15. Slide 15: ATRN-1051 WEE1 Inhibitor

    ATRN-1051 WEE1 Inhibitor 15 © 2023 Aprea Therapeutics, Inc. All Rights Reserved.

  16. Slide 16: ATRN-1051 Has Demonstrated Potentially Compelling Anti-tumor Activity

    ▪ Nanomolar anti-proliferative potency in vitro against multiple cancer cell lines ▪ Potent anti-tumor activity observed in vivo in an ovarian cancer xenograft model (CCNE1-amplified cell line) ATRN-1051 Has Demonstrated Potentially Compelling Anti-tumor Activity IND filing targeted by the end of 20

  17. Slide 17: ATRN-1051 is Potentially Differentiated from Other WEE1 Inhibitors

    ATRN-1051 is Potentially Differentiated from Other WEE1 Inhibitors © 2023 Aprea Therapeutics, Inc. All Rights Reserved. 17 ATRN-1051 shows potential to be potent and structurally differentiated, with high selectivity to limit off-target toxicity Note: Head-to-head studies have not been conducted (1)

  18. Slide 18: ATRN-1051 Preclinical Data Highlight Potentially Favorable PK Properties

    ATRN-1051 Preclinical Data Highlight Potentially Favorable PK Properties 18 ATRN-1051 (1) Zentalis ZN-c3 (2) AstraZeneca AZD-1775 (2) Dose (mg/kg/d) 10 20 40 80 20 40 80 Cmax, ng/mL 1460 1167 1997 5100 635 2460 4703 Tmax, hr 2.7 1 1 1 1 1 1 AUC0-24, ng*hr/mL 16739 4863 17088 39722 1494 6313 13408 No

  19. Slide 19: Intellectual Property

    Intellectual Property © 2023 Aprea Therapeutics, Inc. All Rights Reserved. 19

  20. Slide 20: Intellectual Property Portfolio Of DDR Inhibitors

    Intellectual Property Portfolio Of DDR Inhibitors Four issued US patents protecting lead molecule and analogs ▪ Family 1: Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase Inhibitors ‒ Macrocyclic inhibitors of ATR & methods of using them to treat various cancers, filed on Oct. 13th, 2015

  21. Slide 21: Corporate Highlights & Milestones

    Corporate Highlights & Milestones © 2023 Aprea Therapeutics, Inc. All Rights Reserved. 21

  22. Slide 22: Robust DDR Development Milestones

    Robust DDR Development Milestones © 2022 Aprea Therapeutics, Inc. All Rights Reserved. 22 1 ATRN-354 timeline and anticipated milestones subject to data from ATRN-119 clinical trial

  23. Slide 23: Corporate Summary and Recent Highlights

    Corporate Summary and Recent Highlights © 2023 Aprea Therapeutics, Inc. All Rights Reserved. 23 Robust synthetic lethality (SL) portfolio built in-house from foundational, proprietary DNA damage repair (DDR) platform ◊ Addressing critical unmet therapeutic needs for patients with genetically defined

  24. Slide 24: Financial Summary & Capitalization

    © 2023 Aprea Therapeutics, Inc. All Rights Reserved. 24 Aprea Therapeutics (NASDAQ: APRE) Financial Summary & Capitalization - Cash & Equivalents of $31.0 million as of March 31, 2023 - Closed $4.9M (net) public offering in February 2023 - Obtained non-dilutive funding via research grant from Nation

  25. Slide 25: Precision Oncology through Synthetic Lethality May 2023

    Precision Oncology through Synthetic Lethality May 2023

Aprea Therapeutics — Investor Presentation (May 2023) on 6ix